Abstract
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in the city of Wuhan in late 2019. Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020. The current health care dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care workers.
Highlights
Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, 6Korea University Medical Center, Seoul, Republic of Korea, 7Cardiocentro, Lugano, Switzerland, 8Northwell Health, North Shore University Hospital, Manhasset, New York, 9University of Michigan, Ann Arbor, Michigan, 10VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, 11Antwerp University and University Hospital, Antwerp, Belgium, 12Renmin Hospital of Wuhan University, Wuhan, China, 13Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, 14Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 15Cooper Medical School of Rowan University, Camden, New Jersey, 16Hospital Pró-Cardíaco, Rio de Janeiro, Brazil, 17CardioInfantil Foundation, Cardiac Institute, Bogota, Colombia, 18Bethel University, St
Information is limited, on how parameters such as QTc measured on a single- lead ECG can reliably substitute for 12-lead ECG information.[18,19]
No specific cure exists for COVID-19.28–30 Potential COVID19 therapies, especially hydroxychloroquine and azithromycin, are being investigated in ongoing trials and have been used off-label in many parts of the world
Summary
No specific cure exists for COVID-19.28–30 Potential COVID19 therapies, especially hydroxychloroquine and azithromycin, are being investigated in ongoing trials and have been used off-label in many parts of the world. A recent statement from the US Food & Drug Administration (FDA) “cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems.” (This does not affect FDAapproved uses for malaria, lupus, and rheumatoid arthritis.)[51] Exceptions to this practice are acknowledged to occur in some regions, as these drugs have been used outside the United States without regulatory warnings Under these conditions, or when these drugs are maintained after hospital discharge, consumer mobile ECG devices capable of generating QTc measurements may be used. Electrocardiographic monitoring during clinical trials Several double- and multi-arm blind randomized controlled trials are underway worldwide for COVID-19 outpatients utilizing different medications that may prolong the QT interval.[52–56] These drugs are being tested either alone or in various combinations and are being compared with one another, with differential dosing regimens and/or placebo. These ECGs are transmitted to a remote QTc monitoring site, where the QTc is assessed and monitored over the treatment period
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
